Sign In
Last checked at 
16 Oct 2015 07:00
ο»Ώ
16 October 2015
Β
AllergyΒ TherapeuticsΒ plc
("AllergyΒ Therapeutics"Β orΒ the "Company")
Β
Annual Report and Accounts
Β
Allergy Therapeutics plc, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that the Annual Report and Accounts for the year ended 30 June 2015 are available on the Company's website in the InvestorΒ RelationsΒ section.Β TheyΒ canΒ beΒ locatedΒ at:
www.allergytherapeutics.com/media/1216/atl-financial-statements-june-2015.pdfΒ
Printed copies of the Annual Report and Accounts for the year end 30 June 2015 will be posted to shareholders together with the Notice of the Annual General Meeting on 20 October 2015.
Β
For further information:
Β
Allergy Therapeutics | +44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer | |
Ian Postlethwaite, Finance Director | |
Panmure Gordon | +44 (0) 20 7886 2500 |
Freddy Crossley / Peter Steel / Duncan Monteith, Corporate Finance | |
Tom Salvesen, Corporate Broking | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell |
Β
Β
Note to editors:
Β
AboutΒ AllergyΒ Therapeutics
AllergyΒ TherapeuticsΒ isΒ aΒ specialtyΒ pharmaceuticalΒ companyΒ focused onΒ allergyΒ vaccination. It hasΒ a growing businessΒ achieving revenue in the lastΒ financial year of Β£43Β millionΒ mainlyΒ in Europe through itsΒ own salesΒ and marketingΒ infrastructure andΒ further afield through distributors.
Β
Β
Follow the stocks
